Sizofiran

Drug Profile

Sizofiran

Alternative Names: Schizophyllan; Sizofilan; Sonifilan; Sonifiran; SPG

Latest Information Update: 20 Jan 2011

Price : $50

At a glance

  • Originator Kaken Pharmaceutical
  • Class Antineoplastics; Antivirals; Beta Glucans; Radiosensitisers
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Cervical cancer
  • Discontinued Hepatitis B; Lung cancer

Most Recent Events

  • 31 Dec 1998 Launched for Cervical cancer in South Korea (Unknown route)
  • 26 Aug 1998 Profile reviewed
  • 12 Oct 1994 Preregistration for Lung cancer in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top